Answers are grounded in this paper and cite their sources.
Validation study reveals marked domain sensitivity and performance gains from multiphasic inputs in liver cancer MRI segmentation, highlighting the need for broader prospective validation.
Background/Objectives: To establish an auditable nnU-Net v2 HCC MRI segmentation benchmark, quantify phase- and cohort-dependent transportability without external fine-tuning, evaluate false-positive safety on HCC-negative examinations, and test whether complementary arterial-plus-venous input improves performance in OpenSwissHCC. Methods: A 3D full-resolution nnU-Net was trained by five-fold cross-validation on 60 public ATLAS cases. The unchanged five-fold ensemble was applied separately to arterial, portal/venous, delayed and native T1-weighted images in LiverHccSeg and OpenSwissHCC. All 132 OpenSwissHCC subjects (63 HCC-positive and 69 HCC-negative) underwent inference in every phase; positive-case overlap and detection were reported separately from negative-examination specificity. A patient-paired five-fold ablation compared venous-only with arterial-plus-venous OpenSwissHCC training. MRI-to-CT application to 97 valid-reference HCC-TACE-Seg cases was exploratory. Results: The ATLAS out-of-fold mean Dice was 0.5315 (95% CI 0.4478–0.6126). The OpenSwissHCC positive mean Dice was 0.3388 arterial, 0.1267 venous, 0.1810 delayed and 0.0814 native; the corresponding detection was 55.6%, 28.1%, 27.6% and 23.8%, while the negative-examination specificity ranged from 50.7% to 81.2%. The detection was lower when all of the documented HCCs were <20 mm. Arterial-plus-venous training increased the mean Dice from 0.2269 to 0.3705 (paired difference +0.1435, 95% CI +0.0520 to +0.2343; p = 0.00223) and reduced the false-positive voxel burden (p = 0.0394), although the binary detection increase was not significant by exact McNemar testing (p = 0.0639). The MRI-to-CT mean Dice was 0.0286. Conclusions: The HCC segmentation performance was strongly domain-sensitive. Multiphasic input improved segmentation quality within the cohort, but reliable clinical use requires substantially broader development and prospective validation.
No takes yet. Share an insight, caveat, or question.
George Sgourakis (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: